{
    "root": "2ffeb25a-76aa-01e6-e063-6394a90ae332",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metformin HCL",
    "value": "20250310",
    "ingredients": [
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "metformin hydrochloride tablets indicated adjunct diet exercise improve glycemic control adults pediatric patients 10 years age older type 2 diabetes mellitus .",
    "contraindications": "2.1 adult metformin hydrochloride tablets recommended starting dose metformin hydrochloride tablets 500 mg orally twice day 850 mg day , given meals . increase dose increments 500 mg weekly 850 mg every 2 weeks basis glycemic control tolerability , maximum dose 2,550 mg per day , given divided doses . doses 2,000 mg may better tolerated given 3 times day meals . 2.2 pediatric metformin hydrochloride tablets recommended starting dose metformin hydrochloride tablets pediatric patients 10 years age older 500 mg orally twice day , given meals . increase increments 500 mg weekly basis glycemic control tolerability , maximum 2,000 mg per day , given divided doses twice daily . 2.3 recommendations renal impairment assess renal function prior initiation metformin hydrochloride tablets periodically thereafter . metformin hydrochloride tablets contraindicated patients estimated glomerular filtration rate ( egfr ) 30 ml/minute/1.73 2. initiation metformin hydrochloride tablets patients egfr 30 45 ml/minute/1.73 2 recommended . patients taking metformin hydrochloride tablets whose egfr later falls 45 ml/min/1.73 2 , assess benefit risk continuing therapy . discontinue metformin hydrochloride tablets patient ’ egfr later falls 30 ml/minute/1.73 2 [ ( 5.1 ) ] . 2.4 discontinuation iodinated contrast imaging procedures discontinue metformin hydrochloride tablets time , prior , iodinated contrast imaging procedure patients egfr 30 60 ml/min/1.73 2 ; patients history liver disease , alcoholism , heart failure ; patients administered intra-arterial iodinated contrast . re-evaluate egfr 48 hours imaging procedure ; restart metformin hydrochloride tablets renal function stable .",
    "warningsAndPrecautions": "metformin hydrochloride tablets 500 mg bottles 30 ndc 72189-617-30 white white , round , film-coated tablets free physical defects , debossed `` 001 `` one side `` 500 `` side . bottles 500 ndc 23155-841-05 bottles 1000 ndc 23155-841-10 850 mg bottles 100 ndc 23155-842-01 white white , round , film-coated tablets free physical defects , debossed `` 002 `` one side `` 850 `` side . bottles 500 ndc 23155-842-05 bottles 1000 ndc 23155-842-10 1,000 mg bottles 100 ndc 23155 -843-01 white white , oval , biconvex , film-coated tablets free physical defects , debossed `` 003 `` one side `` 1000 `` side bisect line sides . bottles 500 ndc 23155-843-05 bottles 1000 ndc 23155-843-10",
    "adverseReactions": "metformin hydrochloride tablets contraindicated patients : severe renal impairment ( egfr 30 ml/min/1.73 2 ) [ ( 5.1 ) ] . hypersensitivity metformin . acute chronic metabolic acidosis , including diabetic ketoacidosis , without coma .",
    "indications_original": "Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.",
    "contraindications_original": "2.1 Adult Dosage\n                  Metformin Hydrochloride Tablets\n                  The recommended starting dose of metformin hydrochloride tablets are 500 mg orally twice a day or 850 mg once a day, given with meals.\n  \nIncrease the dose in increments of 500 mg weekly or 850 mg every 2 weeks on the basis of glycemic control and tolerability, up to a maximum dose of 2,550 mg per day, given in divided doses.\n  \nDoses above 2,000 mg may be better tolerated given 3 times a day with meals.\n \n                  2.2 Pediatric Dosage for Metformin Hydrochloride Tablets\n                  The recommended starting dose of metformin hydrochloride tablets for pediatric patients 10 years of age and older is 500 mg orally twice a day, given with meals.\n  \nIncrease dosage in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg per day, given in divided doses twice daily.\n \n                  2.3 Recommendations for Use in Renal Impairment\n                  Assess renal function prior to initiation of metformin hydrochloride tablets and periodically thereafter.\n  \nMetformin hydrochloride tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m 2.\n  \nInitiation of metformin hydrochloride tablets in patients with an eGFR between 30 to 45 mL/minute/1.73 m 2 is not recommended.\n  \nIn patients taking metformin hydrochloride tablets whose eGFR later falls below 45 mL/min/1.73 m 2, assess the benefit risk of continuing therapy.\n  \nDiscontinue metformin hydrochloride tablets if the patient’s eGFR later falls below 30 mL/minute/1.73 m 2 [ see Warnings and Precautions ( 5.1) ].\n \n                  2.4 Discontinuation for Iodinated Contrast Imaging Procedures\n                  Discontinue metformin hydrochloride tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride tablets if renal function is stable.",
    "warningsAndPrecautions_original": "METFORMIN HYDROCHLORIDE Tablets\n  \n500 mg Bottles of 30 NDC 72189-617-30 White to off white, round, film-coated tablets free from physical defects, debossed with \"001\" on one side and \"500\" on the other side.\n  \nBottles of 500 NDC 23155-841-05\n  \nBottles of 1000 NDC 23155-841-10\n  \n850 mg Bottles of 100 NDC 23155-842-01 White to off white, round, film-coated tablets free from physical defects, debossed with \"002\" on one side and \"850\" on the other side.\n  \nBottles of 500 NDC 23155-842-05\n  \nBottles of 1000 NDC 23155-842-10\n  \n1,000 mg Bottles of 100\n \n                  NDC 23155 -843-01\n                  White to off white, oval, biconvex, film-coated tablets free from physical defects, debossed with \"003\" on one side and \"1000\" on the other side and with a bisect line on both sides.\n  \nBottles of 500 NDC 23155-843-05\n  \nBottles of 1000\n \n                  NDC 23155-843-10",
    "adverseReactions_original": "Metformin hydrochloride tablets are contraindicated in patients with:\n                  Severe renal impairment (eGFR below 30 mL/min/1.73 m 2) [ see Warnings and Precautions ( 5.1) ].\n  \nHypersensitivity to metformin.\n  \nAcute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma."
}